Karl-Heinz Altmann

This inventor holds 23 USPTO granted patents and 3 published patent applications and 1 EPO patent, primarily in Oligonucleotide Chemistry. Top assignees: Novartis Ag, Isis Pharmaceuticals, Inc., Ciba-Geigy Corporation. Active years: 1995-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Karl-Heinz Altmann. Retrieved from https://idiyas.com/inventor/karl-heinz-altmann

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 (Patent Applications = 3)

% Patents Active = 60.9

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 3.7

ph-index = 12

Forward Citations = 1,318(Granted Patents)

Location History:

Basel, CH (1995 - 1997)
Reinach, CH (1998 - 2010)

Company Filing History:

Isis Pharmaceuticals, Inc.

patents

4 out of 6,858

Ciba-Geigy Corporation

Schering Aktiengesellschaft

Scripps Research Institute

patents

8. 2 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 1995-2010

Loading Chart...

Areas of Expertise:

Epothilone Derivatives

VEGF Inhibitors

N-Aryl Compounds

Oligonucleotide Derivatives

Angiogenesis Inhibitors

Carbocyclic Nucleosides

Isoquinoline Derivatives

Antisense Oligonucleotides

Nucleoside Synthesis

Protein Kinase Modulation

Cyclopropyl Analogs

Phthalazines

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7825141 - Epothilone derivatives (2010-11-02),

2. 7358266 - Cyclopropyl and cyclobutyl epothilone analogs (2008-04-15),

3. 7002022 - N-Aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF (2006-02-21),

4. 6878720 - VEGF receptor tyrosine kinase inhibitors (2005-04-12),

5. 6710047 - Phthalazines with angiogenesis inhibiting activity (2004-03-23),

6. 6670468 - 2′-substituted nucleosides and oligonucleotide derivatives (2003-12-30),

7. 6608071 - Isoquinoline derivatives with angiogenesis inhibiting activity (2003-08-19),

8. 6514974 - Pyrido-, pyrimido-, pyridazo- and pyrazo- pyridazines having angiogenesis inhibiting activity (2003-02-04),

9. 6451991 - Sugar-modified gapped oligonucleotides (2002-09-17),

10. 6448277 - VEGF receptor tyrosine kinase inhibitors (2002-09-10),

11. 6387927 - Epothilone derivatives and their use as antitumor agents (2002-05-14),

12. 6350878 - Intermediates for the synthesis of epothilones and methods for their preparation (2002-02-26),

13. 6329519 - Intermediates for oligonucleotide synthesis (2001-12-11),

14. 6291668 - Oligonucleotide derivatives (2001-09-18),

15. 6258812 - Phthalazines with angiogenesis inhibiting activity (2001-07-10),

Title: Contributions of Karl-Heinz Altmann to Pharmaceutical Innovation

Introduction

Karl-Heinz Altmann, based in Reinach, Switzerland, is a prominent inventor with a significant portfolio of 23 patents. His work primarily focuses on advancements in pharmaceuticals, particularly in the field of cancer treatment. His innovative contributions have made him a notable figure in the scientific community.

Latest Patents

Altmann's recent patents include groundbreaking work on Epothilone derivatives, which are vital for their use as a pharmaceutical. These compounds have shown promising results in promoting tubulin polymerization and serving as cytotoxic agents in the treatment of neoplastic diseases. Another recent patent pertains to cyclopropyl and cyclobutyl epothilone analogs, where he explores the synthesis and biological evaluation of these compounds, which possess significant therapeutic potential.

Career Highlights

Throughout his career, Altmann has held key positions at renowned companies, including Novartis AG and Isis Pharmaceuticals, Inc. His experience in these organizations has enabled him to contribute extensively to pharmaceutical research and development, culminating in a series of impactful inventions that enhance treatment options for cancer patients.

Collaborations

Karl-Heinz Altmann has collaborated with distinguished colleagues such as Guido Bold and Pierre Martin. These partnerships have facilitated a robust exchange of ideas and expertise, further advancing his research and leading to successful patent applications.

Conclusion

In summary, Karl-Heinz Altmann’s contributions to the pharmaceutical industry are marked by his extensive patent portfolio and innovative research. His latest work on epothilone derivatives and related compounds demonstrates his commitment to developing effective cancer treatments. As he continues to push the boundaries of scientific discovery, his efforts remain influential in the ongoing fight against neoplastic diseases.

Profile summary based on public USPTO records.